Roche, Biogen report one death in MS drug trial

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.

Roche, Biogen report one death in MS drug trial

Postby MSUK » Tue Oct 19, 2010 11:20 pm


Roche Holding AG and Biogen Idec Inc reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.

Data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showed that the drug reduced disease activity by a significant amount as measured by the number of brain lesions and relapse rate. But some side effects were greater in the ocrelizumab arm than in the placebo arm.

In May, Roche of Switzerland and Biogen of Cambridge, Massachusetts, said they would discontinue studies of the drug as a treatment for rheumatoid arthritis after a safety monitoring board ruled that the risk outweighed the benefit in the RA population.... Read More - ... ageid/1397
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm


Postby whyRwehere » Wed Oct 20, 2010 11:11 am

oh, too risky for those arthritis patients, let's give it to the desperate MS ones... :evil:
User avatar
Family Elder
Posts: 917
Joined: Mon Oct 03, 2005 2:00 pm

Postby CCSVIhusband » Wed Oct 20, 2010 11:18 am

WHOA! EVERY neurologist better come out against this drug now ... it's now as bad as CCSVI ...

User avatar
Family Elder
Posts: 475
Joined: Sun Jun 27, 2010 2:00 pm
Location: Pittsburgh, PA USA

Postby rainer » Wed Oct 20, 2010 5:36 pm

I wonder how they studied anything before god's gift of CCSVI came down from the heavens to show science the platonic state of medical perfection. :roll:
User avatar
Family Elder
Posts: 367
Joined: Thu Jan 17, 2008 3:00 pm

Return to Ocrevus (Ocrelizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service